Interim results of Ofatumumab phase II study in MS announced

Kesimpta is a subcutaneously injected anti CD20 monoclonal antibody approved for RRMS and active progressive MS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

Interim results of Ofatumumab phase II study in MS announced

Post by MSUK » Wed Jul 07, 2010 5:02 am

Image

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis (RRMS).

A total of 38 patients were included in the trial, of which 12 patients received placebo and 26 patients received ofatumumab intravenously. Patients were treated with ofatumumab at the dose levels of 100 mg, 300 mg or 700 mg and followed for 24 weeks. ... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/

Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Kesimpta (Ofatumumab)”